SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) — ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the expansion of its ongoing Phase I clinical trial of IDOV-Immune into the United States.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
